To circumvent the confounding effect of the residual mild to moderate hyperglycaemia in these mice, we next examined the TAM-treated Glis3fl/fl/Pdx1CreERT+ mice early at 10 days after TAM administration, when the animals were still euglycaemic and had normal plasma insulin. The gene discussed is INS; the disease is Hyperglycemia.